Historical Stock Price
CELC historical stock prices picture
Celcuity (CELC) has the following price history information. Looking back at CELC historical stock prices for the last five trading days, on April 19, 2024, CELC opened at $16.22, traded as high as $17.26 and as low as $16.17, and closed at $17.24. Trading volume was a total of 232.60K shares. On April 22, 2024, CELC opened at $17.17, traded as high as $17.67 and as low as $16.96, and closed at $17.54. Trading volume was a total of 405.10K shares. On April 23, 2024, CELC opened at $17.56, traded as high as $18.21 and as low as $17.18, and closed at $17.24. Trading volume was a total of 90.60K shares. On April 24, 2024, CELC opened at $17.06, traded as high as $17.27 and as low as $16.91, and closed at $16.94. Trading volume was a total of 90.30K shares. On April 25, 2024, CELC opened at $16.73, traded as high as $16.76 and as low as $15.71, and closed at $15.77. Trading volume was a total of 228.70K shares.

CELC Historical Stock Prices By Date:

CELC historical cagr picture

Below, we examine the compound annual growth rate — CAGR for short — of an investment into Celcuity shares, starting with a $10,000 purchase of CELC, and working forward through the historical stock price information to today.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 09/21/2017
End date: 04/25/2024
Start price/share: $13.41
End price/share: $15.77
Dividends collected/share: $0.00
Total return: 17.60%
Average Annual Total Return: 2.49%
Starting investment: $10,000.00
Ending investment: $11,761.66
Years: 6.60
Date Open High Low Close Volume
04/19/2024 $16.22 $17.26 $16.17 $17.24 232.60K
04/22/2024 $17.17 $17.67 $16.96 $17.54 405.10K
04/23/2024 $17.56 $18.21 $17.18 $17.24 90.60K
04/24/2024 $17.06 $17.27 $16.91 $16.94 90.30K
04/25/2024 $16.73 $16.76 $15.71 $15.77 228.70K
Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for treatment of multiple solid tumor indications. Co.'s main therapeutic candidate is gedatolisib, a pan-PI3K/mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other approved and investigational therapies that target PI3K or mTOR alone or together. Co.'s therapeutic candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all Class I isoforms of PI3K and mammalian target of rapamycin.
Date Close
04/19/2024$17.24
04/22/2024$17.54
04/23/2024$17.24
04/24/2024$16.94
04/25/2024$15.77
CELC is categorized under the Healthcare sector; below are some other companies in the same sector:

CELG Historical Stock Prices
CEMI Historical Stock Prices
CEMP Historical Stock Prices
CERC Historical Stock Prices
CERCU Historical Stock Prices
CERE Historical Stock Prices
CERS Historical Stock Prices
CERU Historical Stock Prices
CFMS Historical Stock Prices
CFN Historical Stock Prices

Also explore: CELC shares outstanding history

Email EnvelopeFree CELC Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts


CELC Historical Stock Prices | www.HistoricalStockPrice.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in www.HistoricalStockPrice.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.